Embla Medical hf., (EMBLA) Fair Value & Analysis
Healthcare · DK · Market cap 11.7B DKK
Analysis
Embla Medical hf., (EMBLA) currently trades at kr 25.95, while our model-based Fair Value estimate is kr 4.46 — implying the stock looks roughly 82.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild an…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.